State of Practice: ASNR Statement on Gadolinium-Based Contrast Agent Use in Patients with Chronic Kidney Disease
For neuroimaging applications, the ASNR recommends that group II GBCAs no longer be withheld in patients with CKD when these agents are medically indicated for diagnosis. Moreover, if group II GBCAs are exclusively used in an MRI practice, other safety measures, such as checking renal function or querying patients about CKD, can be discontinued.
Authors
- Kirk M. Welker (ORCID: https://orcid.org/0000-0003-1293-2887)
- Colin M. Segovis (ORCID: https://orcid.org/0000-0001-5832-0275)
- David S. Liebeskind (ORCID: https://orcid.org/0000-0002-5109-8736)
- Noushin Yahyavi‐Firouz‐Abadi (ORCID: https://orcid.org/0000-0002-0527-1593)
- John E. Jordan (ORCID: https://orcid.org/0000-0002-5779-7538)
- Amit M. Saindane (ORCID: https://orcid.org/0000-0002-2903-3995)
- David Joyner (ORCID: https://orcid.org/0000-0003-1283-3678)
- Anthony Kam (ORCID: https://orcid.org/0000-0002-3746-1041)
Institutions
- University of Maryland, Baltimore (US)
- Loyola University Medical Center (US)
- Mayo Clinic (US)
- Emory University (US)
- European Committee for Standardization (BE)
- University of California, Los Angeles (US)
- Mayo Clinic in Arizona (US)
- Little Company of Mary Hospital (US)
- University of Virginia Medical Center (US)
- Mayo Clinic in Florida (US)
Publication Details
- Journal
- American Journal of Neuroradiology
- Published
- 2024-09-16
- DOI
- https://doi.org/10.3174/ajnr.a8501
- Citations
- 6
- Primary Topic
- Lanthanide and Transition Metal Complexes
- Type
- article
- Field-Weighted Citation Impact
- 0.70